
Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us nowThe chart is not accessible to screen readers. Please switch to the table view to access the data.
With the increase in people suffering from depression worldwide, the cost of this illness has raised concerns. It has been estimated that psychedelic-assisted therapy (PAT) could ease this burden, representing a more effective tool than conventional therapy, especially in the case of treatment-resistant depression. In particular, in the U.S. savings could reach up to billion U.S. dollars. This statistic displays the cost of depression and potential savings with psychedelic-assisted therapies in the U.S. and Europe, as of 2020.
Log in or register to access precise data.
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
About the industry
About the region
Selected statistics
Other regions
Related statistics
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.